logo

Loading..
  • Company
    Company
      • Company
      • Our history
        • Founders
      • Strategy
      • Organization
      • Board of Directors
      • Leadership
      • Governance
        • Corporate Governance Reports
        • Governance structure
        • General meeting
          • Extraordinary General Meeting 2020
          • General Meetings
        • Nomination committee
          • Nomination Committee 2021
          • Nomination Committees
        • The Board of Directors
          • Board of Directors
          • Work of the Board of Directors
          • Board committees
        • Senior Management
        • Remuneration
        • Auditors
        • Internal control
        • Articles of association
  • Innovation
    Innovation
      • Innovation
      • Investigational Drug
        • Mechanism of action
      • Research Areas
        • Multiple Myeloma
        • AL-amyloidosis
      • Investigator-Initiated Trials
      • Selected bibliography
      • Scientific publication/Posters
        • O-12-M1 posters
        • ANCHOR (OP-104) posters
        • HORIZON (OP-106) Posters
        • Pre-clinical Data posters
      • Intellectual Property
  • Pipeline
    Pipeline
      • Pipeline
      • Clinical Development
      • Regulatory
      • O-12-M1
      • HORIZON
      • OCEAN
      • ANCHOR
      • BRIDGE
      • ASCENT
      • PORT
      • LIGHTHOUSE
  • Investors
    Investors
      • Investors
      • Investor Relations Contacts
      • The share
        • Share capital development
        • Dividend policy
        • Ownership structure
        • Analysts
      • Press releases
      • Presentations
      • Financial reports
      • Calendar
      • Prospectus
      • Share issues
        • Share issue May 2020
        • Share issue June 2019
        • Share issue January 2019
        • Share issue March 2018
  • Media
    Media
      • Media
      • Press releases
      • Image bank
      • Media contact
  • Career
    Career
      • Career
      • Career Opportunities
      • Culture & values
  • Contact
    Contact
      • Contact
      • Global Headquarters
      • US Headquarters
Loading..
Loading..

Change region

United States
Global

Change language

English
  • Swedish
MediaPress releases

Press Releases

All press releases
  • Regulatory press releases
  • Other press releases
2014
  • 2020
  • 2019
  • 2018
  • 2017
  • 2016
  • 2015
  • 2014
  • 2013
  • 2011
  • 2010
  • All years

Oncopeptides Presents Encouraging Preliminary Phase I/ II Clinical Data with Melflufen and Dexamethasone for Patients with Relapsed and RelapsedRefractory Multiple Myeloma at the 56th ASH Annual Meeting and Exposition

December 5, 2014 - Other press release
Oncopeptides AB, a clinical stage company developing a novel alkylator – melflufen – today announced that initial clinical data from the dose escalation part of a Phase I/II dose escalation/expansion tri...
Read more
  • Media
    • Press releases
    • Subscribe
    • Image bank
    • Media contact
  • Oncopeptides AB (publ)
  • Registration number: 556596-6438
  • info@oncopeptides.com
  • About cookies
  • Personal Data
  • Glossary

© 2020 Oncopeptides AB (publ). All rights reserved.

Welcome to Oncopeptides AB’s (publ) website. In order to optimize your use of our website we use cookies. A cookie is a text file stored on your computer. If you want more information about what a cookie is, what the purpose of the cookie is and how you can block or delete cookies, please read the our cookie guidelines “About cookies”. By continuing, you agree to our use of cookies.

Close

Global

You are now leaving the global website of Oncopeptides AB, Sweden. The link you clicked will take you to the website of our US operations, Oncopeptides Inc. at www.oncopeptides-us.com

Stay on this page Leave this page